When to Hold Retacrit (Epoetin Alfa)
Hold Retacrit when hemoglobin exceeds a level needed to avoid transfusion, and restart at 25% below the previous dose when hemoglobin approaches a level where transfusion may be required. 1
Context-Specific Thresholds
The specific hemoglobin level at which to hold Retacrit varies by clinical indication:
For Cancer Patients on Chemotherapy
- Withhold dose if hemoglobin exceeds a level needed to avoid RBC transfusion 1
- Reduce dose by 25% when hemoglobin increases >1 g/dL in any 2-week period 2, 3
- Reduce dose by 25% when hemoglobin reaches a level needed to avoid transfusion 2, 3
- The 2019 ASCO/ASH guidelines specify that hemoglobin should be increased to the lowest concentration needed to avoid transfusions, which may vary by patient 2, 3
For Chronic Kidney Disease (CKD) Patients
CKD on Dialysis:
- Reduce or interrupt when hemoglobin approaches or exceeds 11 g/dL 1
- This is the most clearly defined threshold in the FDA labeling
CKD Not on Dialysis:
- Reduce or interrupt when hemoglobin exceeds 10 g/dL 1
- Use the lowest dose sufficient to reduce need for RBC transfusions
Pediatric CKD Patients:
- Reduce or interrupt when hemoglobin approaches or exceeds 12 g/dL 1
For HIV Patients on Zidovudine
- Withhold if hemoglobin exceeds 12 g/dL 1
- Resume at 25% dose reduction when hemoglobin declines to <11 g/dL
Critical Safety Consideration for Rapid Rise
Regardless of absolute hemoglobin level, reduce dose by 25% or more if hemoglobin rises rapidly (>1 g/dL in any 2-week period) to avoid excessive ESA exposure and associated cardiovascular risks. 1, 2
Practical Algorithm
Monitor hemoglobin weekly until stable, then at least monthly 1
Hold the dose when:
- Hemoglobin exceeds target for indication (see above)
- Hemoglobin rises >1 g/dL in 2 weeks (reduce first, then hold if continues)
Restart at 25% dose reduction when hemoglobin approaches level where transfusion may be required 1
Avoid frequent dose adjustments - a single hemoglobin excursion may not require dosing change 1
Important Caveats
The European guidelines (ESMO) recommend withholding when hemoglobin >13 g/dL until it falls to 12 g/dL 4, but US FDA labeling does not specify this absolute threshold, instead focusing on individualized levels needed to avoid transfusion. The FDA approach is more conservative and should be followed in US practice.
Never target hemoglobin >12 g/dL - multiple studies have demonstrated increased mortality and cardiovascular events at higher targets 2, 5. The goal is the lowest hemoglobin sufficient to avoid transfusion, not normalization.